Early Phase Clinical Trial About Therapeutic Biological Product Mix for Treating CEA Positive Rectal Cancer
Running, not enrolling · Phase 1
Conditions studied: Rectal Cancer
In brief
Conducting an early phase clinical trial to assess CEA Antigen Presentation Therapeutic Biological Product Mix activity that suggests the potential for clinical benefit of CEA positive rectal cancer patients. 1. Treat CEA positive rectal cancer via Trained Immunity. 2. Activate human CEA Protein Antigen Presentation Reaction. 3. The human antigen presenting cells (APCs) can treat the CEA protein antigen into small peptide fragments, and then kill CEA positive rectal cancer cells in vivo.
Key facts
- Study ID
- NCT02403505
- Run by
- Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
- People needed
- 20
- Starts
- 2021-12-28
- Expected to finish
- 2026-12-28
- Last updated by the study team
- 2026-05-28
Who can join
Age: 24 and older, up to 64. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Clinical Rectal Cancer Diagnosis Stage 0 - IIA
- Clinical Rectal Cancer Diagnosis without symptoms
- Clinical Rectal Cancer Diagnosis without metastasis
- Positive testing CEA by blood-drawing
- TB negative participant is negative IGRA blood test with TB antigens.
You may not qualify if…
- Pregnant
- Thrombosis
- Allergy
- TB positive participant is positive IGRA blood test with TB antigens.
- Symptoms of rectal cancer
- Metastasis of rectal cancer
- Evidence of critical illness
Where it is running
- Medicine Invention Design, Inc. (MIDI) - c/o - IORG0007849 - NPI-1023387701 — Rockville, Maryland, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.